Format

Send to:

Choose Destination
See comment in PubMed Commons below
Semin Cancer Biol. 2009 Oct;19(5):310-7. doi: 10.1016/j.semcancer.2009.05.006. Epub 2009 Jun 11.

Drug resistance associated with antiangiogenesis therapy.

Author information

  • 1Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA 02115, USA.

Abstract

Neovascularization is one of the hallmarks associated with tumor growth. In the recent years, a number of angiogenesis inhibitors have been approved for clinical use in cancer patients. However, the efficacy of antiangiogenic therapy is in most cases short-lasting, with likely drug resistance developing within a few months. It is becoming clear also that there are a subset of malignant tumors that are inherently resistant to angiogenesis inhibition. The knowledge regarding resistance mechanisms towards angiogenesis inhibitors is still evolving and here we propose some theories and in some cases provide experimental evidence.

PMID:
19524042
[PubMed - indexed for MEDLINE]
PMCID:
PMC4001703
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk